![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ROBO1 |
Gene summary for ROBO1 |
![]() |
Gene information | Species | Human | Gene symbol | ROBO1 | Gene ID | 6091 |
Gene name | roundabout guidance receptor 1 | |
Gene Alias | DUTT1 | |
Cytomap | 3p12.3 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9Y6N7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6091 | ROBO1 | CA_HPV_3 | Human | Cervix | CC | 1.01e-03 | 5.44e-02 | 0.0414 |
6091 | ROBO1 | CCI_1 | Human | Cervix | CC | 2.67e-08 | 1.62e+00 | 0.528 |
6091 | ROBO1 | CCI_2 | Human | Cervix | CC | 3.41e-02 | 7.07e-01 | 0.5249 |
6091 | ROBO1 | CCI_3 | Human | Cervix | CC | 1.20e-19 | 1.62e+00 | 0.516 |
6091 | ROBO1 | LZE8T | Human | Esophagus | ESCC | 1.62e-09 | 4.10e-01 | 0.067 |
6091 | ROBO1 | LZE24T | Human | Esophagus | ESCC | 1.83e-05 | 2.10e-01 | 0.0596 |
6091 | ROBO1 | P1T-E | Human | Esophagus | ESCC | 3.72e-02 | 7.70e-02 | 0.0875 |
6091 | ROBO1 | P2T-E | Human | Esophagus | ESCC | 7.94e-36 | 6.45e-01 | 0.1177 |
6091 | ROBO1 | P4T-E | Human | Esophagus | ESCC | 1.71e-15 | 4.09e-01 | 0.1323 |
6091 | ROBO1 | P10T-E | Human | Esophagus | ESCC | 4.93e-13 | 2.07e-01 | 0.116 |
6091 | ROBO1 | P11T-E | Human | Esophagus | ESCC | 2.93e-07 | 3.78e-01 | 0.1426 |
6091 | ROBO1 | P12T-E | Human | Esophagus | ESCC | 5.84e-08 | 1.45e-01 | 0.1122 |
6091 | ROBO1 | P16T-E | Human | Esophagus | ESCC | 2.64e-08 | 6.01e-02 | 0.1153 |
6091 | ROBO1 | P20T-E | Human | Esophagus | ESCC | 1.26e-33 | 7.99e-01 | 0.1124 |
6091 | ROBO1 | P22T-E | Human | Esophagus | ESCC | 5.81e-04 | 1.26e-03 | 0.1236 |
6091 | ROBO1 | P23T-E | Human | Esophagus | ESCC | 9.08e-22 | 5.95e-01 | 0.108 |
6091 | ROBO1 | P24T-E | Human | Esophagus | ESCC | 9.29e-09 | 1.88e-01 | 0.1287 |
6091 | ROBO1 | P26T-E | Human | Esophagus | ESCC | 1.55e-12 | 3.99e-01 | 0.1276 |
6091 | ROBO1 | P27T-E | Human | Esophagus | ESCC | 8.59e-21 | 4.56e-01 | 0.1055 |
6091 | ROBO1 | P30T-E | Human | Esophagus | ESCC | 2.58e-03 | 1.93e-01 | 0.137 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005254710 | Cervix | CC | regulation of peptidase activity | 112/2311 | 461/18723 | 6.70e-13 | 3.08e-10 | 112 |
GO:004586210 | Cervix | CC | positive regulation of proteolysis | 95/2311 | 372/18723 | 1.84e-12 | 6.86e-10 | 95 |
GO:005254810 | Cervix | CC | regulation of endopeptidase activity | 103/2311 | 432/18723 | 1.89e-11 | 5.14e-09 | 103 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:00510566 | Cervix | CC | regulation of small GTPase mediated signal transduction | 75/2311 | 302/18723 | 1.54e-09 | 1.74e-07 | 75 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:001095210 | Cervix | CC | positive regulation of peptidase activity | 54/2311 | 197/18723 | 8.06e-09 | 6.99e-07 | 54 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:200011610 | Cervix | CC | regulation of cysteine-type endopeptidase activity | 61/2311 | 235/18723 | 8.69e-09 | 7.22e-07 | 61 |
GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
GO:004328110 | Cervix | CC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 55/2311 | 209/18723 | 2.77e-08 | 1.95e-06 | 55 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:001095010 | Cervix | CC | positive regulation of endopeptidase activity | 48/2311 | 179/18723 | 1.12e-07 | 5.71e-06 | 48 |
GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0436012 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0436016 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0436017 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0436014 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa0436015 | Oral cavity | OSCC | Axon guidance | 97/3704 | 182/8465 | 5.59e-03 | 1.33e-02 | 6.76e-03 | 97 |
hsa0436023 | Oral cavity | EOLP | Axon guidance | 38/1218 | 182/8465 | 1.02e-02 | 2.80e-02 | 1.65e-02 | 38 |
hsa0436033 | Oral cavity | EOLP | Axon guidance | 38/1218 | 182/8465 | 1.02e-02 | 2.80e-02 | 1.65e-02 | 38 |
hsa0436041 | Oral cavity | NEOLP | Axon guidance | 37/1112 | 182/8465 | 4.02e-03 | 1.64e-02 | 1.03e-02 | 37 |
hsa0436051 | Oral cavity | NEOLP | Axon guidance | 37/1112 | 182/8465 | 4.02e-03 | 1.64e-02 | 1.03e-02 | 37 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ROBO1 | SNV | Missense_Mutation | c.4694A>G | p.Asn1565Ser | p.N1565S | Q9Y6N7 | protein_coding | tolerated_low_confidence(0.29) | benign(0) | TCGA-BR-8589-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ROBO1 | SNV | Missense_Mutation | c.1178T>G | p.Leu393Arg | p.L393R | Q9Y6N7 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-8589-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ROBO1 | SNV | Missense_Mutation | c.4921N>T | p.Asp1641Tyr | p.D1641Y | Q9Y6N7 | protein_coding | tolerated_low_confidence(0.14) | benign(0.193) | TCGA-BR-8680-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | CR | |
ROBO1 | SNV | Missense_Mutation | rs377297596 | c.1073G>A | p.Arg358His | p.R358H | Q9Y6N7 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-BR-A4QL-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | CR |
ROBO1 | SNV | Missense_Mutation | c.3314N>G | p.Gln1105Arg | p.Q1105R | Q9Y6N7 | protein_coding | tolerated(0.09) | benign(0.159) | TCGA-BR-A4QM-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
ROBO1 | SNV | Missense_Mutation | novel | c.815C>A | p.Ala272Glu | p.A272E | Q9Y6N7 | protein_coding | deleterious(0) | possibly_damaging(0.901) | TCGA-CD-8533-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | capecitabine | PD |
ROBO1 | SNV | Missense_Mutation | c.3508N>G | p.Arg1170Gly | p.R1170G | Q9Y6N7 | protein_coding | tolerated(0.14) | benign(0.09) | TCGA-CD-A486-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | taxol | PD | |
ROBO1 | SNV | Missense_Mutation | c.3049N>T | p.Ala1017Ser | p.A1017S | Q9Y6N7 | protein_coding | tolerated(0.43) | benign(0.171) | TCGA-CD-A486-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Chemotherapy | taxol | PD | |
ROBO1 | SNV | Missense_Mutation | rs377370843 | c.206N>A | p.Arg69His | p.R69H | Q9Y6N7 | protein_coding | tolerated(0.09) | probably_damaging(0.982) | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ROBO1 | SNV | Missense_Mutation | c.4662N>T | p.Gln1554His | p.Q1554H | Q9Y6N7 | protein_coding | deleterious(0) | benign(0.001) | TCGA-CD-A4MI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |